Mr. Zubizarreta originally joined Immunophotonics as a Director, bringing decades of leadership experience and strategic insight to the board. He is a visionary technology executive and entrepreneur with a distinguished track record of building and scaling innovative companies across multiple industries, including enterprise software and biotechnology. In September 2025, he was appointed CEO of Immunophotonics. This marks a pivotal moment in the company’s evolution, as it advances its lead product, IP-001, through clinical development and prepares for broader commercialization. Under his leadership, Immunophotonics is poised to accelerate its mission of transforming cancer care through novel immune-stimulating drugs. Mr. Zubizarreta served as Chief Technology Officer and Executive Vice President at Hyland Software, Inc., where he was instrumental in the growth of OnBase, one of the world’s leading enterprise content management platforms. His tenure at Hyland helped shape the company into a billion-dollar business, widely adopted across healthcare, government, and financial services sectors. He brings a rare combination of technical depth, operational discipline, and entrepreneurial vision. His leadership is expected to drive investor value and strategic growth as the company expands its clinical pipeline.